跳至主要内容
临床试验/NCT05057572
NCT05057572已完成不适用

Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices- A Randomised Controlled Trial"

Institute of Liver and Biliary Sciences, India1 个研究点 分布在 1 个国家目标入组 104 人开始时间: 2021年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
104
试验地点
1
主要终点
Complicated ascites (any of refractory ascites, SBP, AKI-HRS)

研究概览

简要总结

The cumulative risk of refractory ascites is in the order of 20% within five years of the development of ascites. An elevated sinusoidal pressure is essential for the development of ascites, as fluid accumulation does not develop at portal pressure gradient below 8 mm Hg, and rising corrected sinusoidal pressure correlates with decreased 24-hour urinary excretion of sodium.More recently, it has been hypothesised that bacterial translocation associated with portal hypertension in cirrhosis and related pathogen-associated, molecular pattern activated innate immune responses lead to systemic inflammation.This is associated with vasodilatation as well as release of proinflammatory cytokines, reactive oxygen and nitrogen species, contributing to organ dysfunction.This activates sympathetic nervous system stimulating reabsorption of sodium in proximal,distal tubules, loop of Henle and collecting duct as well as the renin-angiotensin-aldosterone system, leading to sodium absorption from distal tubule and collecting duct.[5]Renal sodium retention and eventual free water clearance due to non-osmoticrelease of arginine-vasopressin and its action on V2 receptor in the collectingduct underlie the fluid retention associated with oedema and ascites in cirrhosis.The lowering of portal pressure using non selective beta blocker has also been shown to reduce the development of ascites, refractory ascites and hepatorenal syndrome.Furthermore, the effect of non slective beta blocker on intestinal permeability, bacterial translocation and inflammatory response has been proposed to mitigate the risk of developing spontaneous bacterial peritonitis.

详细描述

AIM-To compare the safety and efficacy of addition of carvedilol to SMT (diuretics +/- albumin) compared to SMT alone in the prevention of complicated ascites (refractory ascites, AKI-HRS, SBP or severe hyponatremia) at 1year.

Methodology:

Study population: Patient of liver cirrhosis presenting with uncomplicated ascites and without high risk esophageal varices.

Study design:

  • A prospective, randomized, single center open label study.
  • The study will be conducted on the consecutive patients presenting with uncomplicated ascites and low risk esophageal varices seen at the outpatient clinics/wards of Department of Hepatology, ILBS, New Delhi from July 2021 to June 2023.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-65 years
  • Liver cirrhosis
  • Grade II-III high SAAG ascites
  • Small low risk or no esophageal varices

排除标准

  • Age <18 years
  • AKI at enrollement (Prior transient volume responsive AKI stage I included)
  • Post renal or liver transplantation
  • History of CAD, PVD, ventricular arrythmia, Bronchial asthma
  • SBP at diagnosis
  • Severe Hyponatremia (Na <125 MEq/L)
  • Grade II/III/IV HE
  • Advanced HCC (BCLC C,D), PVTT, Pregnancy or Lactating mother
  • High risk varices (Large varices or small high risk varices)
  • Mixed / TB ascites
  • Bilirubin >5 mg/dl
  • Known CKD, obstructive uropathy
  • Patient on MV, NIV, systemic sepsis and shock
  • Lack of informed consent
  • Prior intolerance or S/E to carvedilol or diuretics

研究组 & 干预措施

Carvedilol with Standard Medical Treatment

Experimental

Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP >90, HR >55.

干预措施: Carvedilol (Drug)

Carvedilol with Standard Medical Treatment

Experimental

Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP >90, HR >55.

干预措施: Standard Medical Treatment (Drug)

Standard Medical Treatment

Active Comparator
  • Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.

干预措施: Standard Medical Treatment (Drug)

结局指标

主要结局

Complicated ascites (any of refractory ascites, SBP, AKI-HRS)

时间窗: 1 year

次要结局

  • Incidence of PICD in 1 year(1 year)
  • Mortality(1 year)
  • Incidence of SBP in both groups(1 year)
  • Incidence of severe hyponatremia in both groups(1 year)
  • Maximum tolerated dose of carvedilol(1 year)
  • Ascites resolution in both groups(1 year)
  • Need and frequency of Large Volume Paracentesis(1 year)
  • Tretament (carvedilol) related adverse events and their grades(1 year)
  • Incidence of HE in both groups(6 months)
  • Incidence of variceal bleed in both groups(1 year)
  • Incidence of AKI in both groups(1 year)
  • Change in grade of varices in both groups(1 year)
  • Reduction in HVPG in both groups(1 year)
  • Change in MELD score in both groups(1 year)
  • Change in CTP score in both groups(1 year)
  • Incidence of HE in both groups.(1 year)
  • Incidence of refractory ascites in both groups(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验